|drug4014||olfactory device Wiki||1.00|
There is one clinical trial.
Phase 3 is a randomized clinical trial of yoga vs group Cognitive Behavioral Therapy (CBT) for adolescents with depression.
Description: Acceptability assessed with Qualitative interviewMeasure: Qualitative interview Time: post intervention (month 3)
Description: Credibility assessed with Credibility Expectancy Questionnaire (CEQ), credibility subscale. The credibility subscale of the CEQ, is a 3 item subscale of the 6 item CEQ. The 3 items are measured on a 1-9 scale (not at all - very), Higher scores indicate greater credibility.Measure: Credibility Expectancy Questionnaire (CEQ) - Credibility Subscale Time: Week 1
Description: Patient expectations assessed with the Credibility Expectancy Questionnaire (CEQ), expectancy subscale. The expectancy subscale is a 3 item subscale of the 6 item CEQ. One of the 3 items are measured on a 1-9 scale (not at all - very), 2 are on a 0-10 scale (0-100%). Higher scores indicate greater expectations.Measure: Credibility Expectancy Questionnaire (CEQ) - Expectancy Subscale Time: Week 1
Description: Satisfaction with treatment assessed with The Client Satisfaction Questionnaire (CSQ-8). The CSQ-8 is an 8-item measure with each item measured on a 1-4 scale. Higher scores indicate greater client satisfaction.Measure: The Client Satisfaction Questionnaire (CSQ-8) Time: Post intervention (month 3)
Description: Yoga home practice assessed with a Home practice questionnaire. Duration, frequency, and type of formal and informal home yoga practice between class sessions.Measure: Home practice questionnaire Time: Post intervention (month 3)
Description: Participant safety/adverse events will be measured using the SAFTEE. Participants will also be asked weekly if they experienced any injuries as a result of yoga.Measure: Systematic assessment of treatment-emergent events-general inquiry (SAFTEE) Time: Post intervention (month 3)
Description: Change in depression symptom severity will be assessed via blind evaluator using the the QIDS. The QIDS is a 17 item measure with scores ranging from 0-30. Higher scores indicate greater depressive symptoms.Measure: Quick Inventory of Depression - Adolescent Version - Clinician Rating (QIDS-A-CR) Time: Baseline to post intervention (month 3); Baseline to 6 months; Baseline to 9 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports